Literature DB >> 2912405

Community- and hospital-acquired pneumonia associated with Chlamydia TWAR infection demonstrated serologically.

J T Grayston1, V K Diwan, M Cooney, S P Wang.   

Abstract

Serum specimens from 198 patients with pneumonia hospitalized in Seattle between October 1980 and April 1981 were retrospectively tested for antibody against a recently described Chlamydia organism called TWAR. They had been previously tested for antibody for some viruses and Mycoplasma. Twenty (10%) had serologic evidence of recent TWAR infection. The hospital records of the patients with acute TWAR antibody and an equal number of matched controls were examined for clinical characteristics, laboratory tests, treatment, and course during the hospital stay. It was not possible clinically or roentgenographically to distinguish pneumonia associated with TWAR antibody from pneumonia in the controls. Nine of 20 patients with TWAR antibody acquired pneumonia during their hospital stay. The mode of transmission in the hospital was not determined. All the patients with hospital-acquired pneumonia had been intubated, and all had had some surgical procedure. Ten of 20 control patients had onset of their pneumonia in the hospital. Fifteen (11%) of 142 of the patients with pneumonia had evidence of influenza A virus infection. The clinical characteristics of their pneumonias were similar to those of the patients with acute TWAR antibody.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2912405

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  28 in total

1.  Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis.

Authors:  L A Jackson; L A Campbell; R A Schmidt; C C Kuo; A L Cappuccio; M J Lee; J T Grayston
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Antigenic and molecular analyses of different Chlamydia pneumoniae strains.

Authors:  C A Jantos; S Heck; R Roggendorf; M Sen-Gupta; J H Hegemann
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

3.  Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group.

Authors:  J F Plouffe; M T Herbert; T M File; I Baird; J N Parsons; J B Kahn; K T Rielly-Gauvin
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.

Authors:  T M File; J Segreti; L Dunbar; R Player; R Kohler; R R Williams; C Kojak; A Rubin
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

5.  Age-related interference with Chlamydia pneumoniae microimmunofluorescence serology due to circulating rheumatoid factor.

Authors:  R P Verkooyen; M A Hazenberg; G H Van Haaren; J M Van Den Bosch; R J Snijder; H P Van Helden; H A Verbrugh
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

Review 6.  Chlamydia pneumoniae: defining the clinical spectrum of infection requires precise laboratory diagnosis.

Authors:  S J Bourke; N F Lightfoot
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

7.  Chlamydia pneumoniae.

Authors:  T J Marrie
Journal:  Thorax       Date:  1993-01       Impact factor: 9.139

8.  Detection of Chlamydia pneumoniae and Chlamydia psittaci in sputum samples by PCR.

Authors:  C Y Tong; M Sillis
Journal:  J Clin Pathol       Date:  1993-04       Impact factor: 3.411

9.  Prevalence of Chlamydia pneumoniae antibodies in patients with acute respiratory infections in Israel.

Authors:  M Ben-Yaakov; Z Lazarovich; S Beer; A Levin; I Shoham; I Boldur
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

10.  Acute lower respiratory tract infection associated with Chlamydia pneumoniae in Germany.

Authors:  C Jantos; P Artelt; H G Schiefer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-01       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.